Kailera touts late-stage win for weight-loss drug in China
Up to 88% of participants who received the drug, known as KAI-9531 outside China, lost at least 5% of their weight after 48 weeks compared to placebo, meeting the study's main goals.
The data comes at a time when U.S. drugmakers are increasingly looking to China to secure the rights to promising drug candidates at a lower cost and access important early data that could pave the way for global trials.
"As we think about commercial opportunity, this is a really good first look as to what we think we're going to be able to leverage in terms of (obesity treatment) marketplace going forward," Kailera CEO Ron Renaud said.
The startup was launched last year with a rare $400 million early-stage funding and four obesity drug candidates licensed from Hengrui, in a move to grab a slice of the obesity treatment market primed to be worth $150 billion by the end of the decade.
KAI-9531, administered as a weekly injection, belongs to a the GLP-1 class of treatments that include Eli Lilly's (LLY.N), opens new tab Zepbound and Novo Nordisk's (NOVOb.CO), opens new tab Wegovy.
The drugs work by helping control blood sugar levels and triggering a feeling of fullness.
"Where we're really focused is where weight loss matters most, which is in people living with higher BMIs (body mass index)," Chief Commercial Officer Jamie Coleman said.
"Today's treatments...leave a lot of clinical need on the table for people who need to lose more than 20% (of weight)."
In the study that included 567 participants, a six-milligram dose of the drug led to an average weight loss of 17.7% compared to placebo.
The companies said the side effects were mild to moderate and gastrointestinal-related, consistent with similar treatments.
Hengrui plans to seek regulatory approval in China, while Kailera will pursue global trials with higher doses and extended treatment durations.
Earlier this year, an eight-milligram dose of the drug led to an average weight loss of 22.8% in a mid-stage trial.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
an hour ago
- The Sun
Man left with riddled with ulcer-like boils 24 hours after catching bubonic plague from pet cat
A MAN started growing boils up his arm just hours after catching the bubonic plague from his pet cat. The 73-year-old from Oregon, US, had accidentally cut his finger with a kitchen knife in January of 2024 before touching the feline. 5 5 The cat was already on antibiotics for an infection, thought to be a neck abscess, at the time. Within a day, a "tender" ulcer appeared on his wrist, according to a paper in the US Centers for Disease Control and Prevention's Morbidity and Mortality Weekly Report. Over the next several hours, the infection spread, causing redness and bumps called buboes that extended up his arm toward his armpit. Buboes are swollen lymph nodes that enlarge and become tender due to the infection. If left untreated, the infection can cause the skin over the buboes to turn black and die, which is where the plague gets its name, the 'Black Death.' Four days later, the pensioner went to hospital, where doctors put him on antibiotics. Tests later confirmed he was infected with Yersinia pestis, the bacteria that causes plague, according to US Centre for Disease Controls Morbidity and Mortality Weekly Report, Medics then switched him onto stronger plague-fighting drugs, including gentamicin and levofloxacin, and he began to improve. He was kept in hospital for over a week and sent home with more medication to finish recovering. At a check-up days later, he was back on his feet, although still feeling wiped out. Though many believe the medieval disease is long gone, some countries still suffer deadly outbreaks of plague due to animals carrying the bacteria. In recent years, it has reported in the US, Peru, China, Bolivia, Uganda, Tanzania and Russia. Experts writing the report, published last week, said the case marked the earliest the bubonic plague has struck in Oregon, with previous cases usually hitting from May onwards. They believe rising winter temperatures could be helping plague, carrying fleas stay active longer, increasing the risk of off-season outbreaks. The man's cat later died after surgery because the owner was unable to give it antibiotics. Tests later confirmed the cat was positive for the same deadly plague bacteria that infected the man. The infectious bacterial disease is carried by wild rodents and their fleas. Officials haven't confirmed exactly how the infection passed from the cat to its owner, but if the cat was bitten by infected fleas, it could have brought the bacteria or fleas into the home, exposing the man. 5 Cats are especially vulnerable to plague because their immune systems struggle to fight off the infection. Plus, they're more likely than many other pets to hunt and catch rodents carrying infected fleas, increasing their risk of contracting, and spreading, the disease. Plague remains on both the WHO and UK Health Security Agency's (UKHSA) priority pathogen lists due to its potential to cause a pandemic. The WHO estimates between 1,000 and 2,000 cases of plague occur globally each year. Though now rare and treatable with antibiotics, plague can still be deadly. The three types of plague Plague takes a few forms. Bubonic plague, the most common form. The main symptoms include buboes, usually in the neck, groin, thighs, or armpits. They may also burst open, releasing the pus inside. Septicemic plague occurs when the infection spreads to the bloodstream. It can develop on its own or as a complication of bubonic plague, causing symptoms like fever, abdominal pain, shock, and bleeding into the skin and organs. Pneumonic plague, the deadliest form, is fatal in up to 90 per cent of patients if left untreated. It often develops when untreated bubonic or septicemic plague spreads to the lungs. But it can also be caught from inhaling the respiratory droplets (e.g. via coughing or sneezing) from an infected person. It infects the lungs and can spread rapidly between humans through airborne droplets. Symptoms include fever, cough, difficulty breathing, and sometimes coughing up blood. Pneumonic plague requires immediate medical attention. Last week, health officials in Arizona announced that a man had died from pneumonic plague just 24 hours after his symptoms began. 5 Risk to Brits is 'very low' On average, there are seven human plague cases are reported in the US each year, according to the CDC. Meanwhile, plague is no longer found in the UK, and the risk of imported cases is considered 'very low,' according to government guidance. However, Covid jab scientists are developing a Black Death vaccine over fears the disease could re-emerge and kill millions. The team behind the Oxford AstraZeneca coronavirus vaccine said they had made progress on an injection that could prevent bubonic plague from developing. The last significant British outbreak occurred in Suffolk in 1918, though a few isolated cases have been suspected since. History of the Black Death THE Black Death was an epidemic of bubonic plague which struck Europe and Asia in the 1300s. It killed more than 20 million people in Europe and about 25 million more across Asia and North Africa, totaling roughly 45 million deaths worldwide. Scientists now know the plague was spread by a bacillus known as yersina pestis. Bubonic plague can cause swelling of the lymph nodes. If untreated, it could spread to the blood and lungs. Other symptoms included fever, vomiting and chills. Physicians relied on treatments such as boil-lancing to bathing in vinegar as they tried to treat people with the plague. Some believed that the Black Death was a "divine punishment" - a form of retribution for sins against God
Telegraph
2 hours ago
- Telegraph
Fat jab makers bet on NHS to be role model for the world
Britain is too fat. One in four people is classed as obese and, on average, they will live nine years less than if they were a healthy weight. They are three times more likely to develop colon cancer and five times more likely to develop type 2 diabetes. Such statistics are not just a crisis in national health, they are also an economic nightmare for the NHS. 'Obesity has doubled since the 1990s and costs our NHS £11bn a year, triple the budget for ambulance services,' Health Secretary Wes Streeting said last month. 'Unless we curb the rising tide of cost and demand, the NHS risks becoming unsustainable.' It is a threat that the Government is taking seriously, with a new ambition to tackle the problem once and for all. 'We now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity,' Streeting says. A crucial part of the plan is the wide rollout of weight-loss injections which, up until this point, have largely been reserved for those who can afford them. The Government instead wants fat jabs to be available 'based on need and not the ability to pay' and is testing new approaches to speed up the rollout of obesity medicines. Public health officials are not the only ones watching closely. At Danish giant Novo Nordisk, which makes obesity jab Wegovy and diabetes drug Ozempic, which can be used off-label for weight loss, executives are eager to know what ministers' next step will be. Sebnem Avsar Tuna, its UK chief, says that the Government's plans could prove a game-changer for Novo Nordisk, showing the benefits of these medicines to the world. 'I think there's a big opportunity for the UK to be a role model,' she says. 'We just need to speed up in terms of getting into the actions, so it's not just on paper ... This is what needs to be shown, at the population health scale, to the entire world: what could be the outcome in a real-world setting.' Test case for the world In other words, Britain could be the test case for the world. If Wegovy can dramatically improve Britain's health – and cut costs – then surely other countries will follow. The Government says it is exploring whether it could bring in a new payment model for weight-loss treatments, so that it would pay pharmaceutical companies based on how well their drugs made the nation healthier. For now, details over the Government's plans remain sparse. The fat jab plans are part of a wider obesity strategy, which also includes curbing calories in supermarkets and getting the country exercising. Ministers have yet to publish a comprehensive strategy. The pharmaceutical industry is not yet clear on which weight-loss drugs could be offered more broadly, nor how they will be rolled out to patients or whether weight limits guiding who can qualify for the jabs will be softened. So far only Eli Lilly's skinny jab Mounjaro is offered on the NHS through GPs. Novo's obesity jab is currently just available through specialist weight management clinics on the public health service, although can be bought privately. Still, both jabs have strict requirements over who is eligible. A person would need to have a BMI of over 40 – classing them as severely obese – as well as at least four of five specific health conditions, which include type 2 diabetes and sleep apnea, to qualify for a weight loss jab when seeking the treatment through a GP. There are concerns that current limits means the drugs are too restricted. 'We should be doing it for people who are becoming obese,' says one government adviser. 'That way, we can get them down to something that looks close to a normal range and then they can go back to work and start paying taxes.' Old habits die hard However, there are concerns that public health officials may resist a broad roll-out of the fat jabs after years where obesity was viewed as a behavioural issue, not something to be treated with medicine. 'The problem is this is very contrary to the status quo in this field, which is: we think you should stop eating, and then you won't be as fat,' the adviser says. There is a 'culture war within the health system between the old school public health doctors who say it's all about behavioural change, and the people who say, 'Hang on a minute, we haven't done so bad with statins, we should do the same with obesity''. 'Wes is probably more inclined to go for the latter view. The trouble is, Wes is not making the decisions. It's being made by a whole load of old-school doctors.' Drug bosses are anxious to see any signs of progress. 'We just need to speed up in terms of getting it done,' says Avsar Tuna. A speedy roll-out could provide not just a boost for Britain's health but also a shot in the arm for Novo Nordisk, which has been struggling in the US. It has faced weaker demand for Wegovy after a boom in cheap replica fat jabs. In May it blamed the copycat drugs – which were allowed by US regulators because of supply issues at Novo Nordisk – for forcing it to slash sales and profit forecasts. Lars Fruergaard Jørgensen was unexpectedly ousted as chief executive at the same time. The arms race in weight loss Regulators have since banned the cheap replicas. Still, it is facing a more existential threat in the form of rival Eli Lilly, amid growing uptake of the US company's Mounjaro weight-loss jab. In a recent head-to-head trial, Mounjaro beat Novo's Wegovy for weight-loss. Barclays analyst Emily Field says she has heard anecdotally that patients prefer Mounjaro too. 'When you look at the side effects in terms of patients that discontinue the drug because they're not feeling well, the two drugs look very similar,' she says. 'But when you actually talk to doctors, they disagree with that. They say that patients just feel better on the Lilly drug.' Novo Nordisk has been racing to develop new medicines to show it can compete, though investors are not entirely convinced. Its share price is down more than 50pc over the past year. Field says the company was 'really hampered' by the fact it was hit by shortages last year. Avsar Tuna says the company has enough capacity to meet demand. 'I can say that we don't have any supply challenges,' she says. If the NHS were to rapidly step up orders, she believes Novo Nordisk could deliver. 'I think it's a positive problem to look at,' Avsar Tuna says. 'If the NHS really comes back and says, tomorrow, I want X number of products from you to be able to give it all to patients, that would be a good dream to have.' Whether the call will come is another matter. Government advisers remain concerned that public health chiefs will try to stand in the way of a sweeping roll-out. 'If you ask me, they're in a bit of a muddle about these drugs,' says one insider. Still, Streeting is clearly convinced that they are the answer to Britain's weight problems. 'This Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay,' the Health Secretary said last month. 'There can be no doubt that these drugs will support our shift from sickness to prevention and be a game-changer for millions.'
Reuters
3 hours ago
- Reuters
FDA appoints George Tidmarsh as top drug regulator
July 21 (Reuters) - U.S. Food and Drug Administration commissioner Marty Makary has appointed former biotech executive George Tidmarsh as the director of the Center for Drug Evaluation and Research, the health regulator said on Monday.
